Hologic (HOLX) Shares are Up 0.99%

Hologic (HOLX) : Traders are bullish on Hologic (HOLX) as it has outperformed the S&P 500 by a wide margin of 1.38% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.82%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.99% in the last 1 week, and is up 0.83% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 1.77% and the 50-Day Moving Average is 1.54%.The 200 Day SMA reached 8.05%


Hologic (NASDAQ:HOLX): After opening at $38.39, the stock dipped to an intraday low of $38.16 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $38.97 and the buying power remained strong till the end. The stock closed at $38.83 for the day, a gain of 1.81% for the day session. The total traded volume was 1,864,886. The stocks close on the previous trading day was $38.83.

Hologic (HOLX) : The consensus price target for Hologic (HOLX) is $42.54 for the short term with a standard deviation of $2.5. The most optimist securities analyst among the 13 who monitor the stock believes that the stock can reach $46, however, the pessimist price target for the company is $39.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *